Comparing Scinai Immunotherapeutics (NASDAQ:SCNI) and Barinthus Biotherapeutics (NASDAQ:BRNS)

Scinai Immunotherapeutics (NASDAQ:SCNI) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Institutional and Insider Ownership

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Scinai Immunotherapeutics and Barinthus Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Barinthus Biotherapeutics	1	0	2	0	2.33

Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 487.29%. Given Barinthus Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Scinai Immunotherapeutics.

Earnings & Valuation

This table compares Scinai Immunotherapeutics and Barinthus Biotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.15 million	1.99	$4.80 million	($9.57)	-0.07
Barinthus Biotherapeutics	$14.97 million	1.86	-$61.07 million	($1.88)	-0.36

Scinai Immunotherapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Scinai Immunotherapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.67, suggesting that its share price is 167% less volatile than the S&P 500.

Profitability

This table compares Scinai Immunotherapeutics and Barinthus Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Barinthus Biotherapeutics	N/A	-70.13%	-56.09%

Summary

Scinai Immunotherapeutics beats Barinthus Biotherapeutics on 7 of the 13 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.